RHHBF:OTC-Roche Holding AG (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 346.01

Change

0.00 (0.00)%

Market Cap

USD 248.88B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-07 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 248.79B
RHHVF Roche Holding AG Participation

N/A

USD 248.79B
AZNCF AstraZeneca PLC

N/A

USD 214.99B
SNYNF Sanofi

N/A

USD 127.02B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 93.38B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 45.22B
ALPMF Astellas Pharma Inc

N/A

USD 17.22B
ALPMY Astellas Pharma Inc

N/A

USD 16.79B
RICFY Recordati Industria Chimica e ..

N/A

USD 14.03B
CSPCY CSPC Pharmaceutical Group Limi..

N/A

USD 8.62B

ETFs Containing RHHBF

TDIV:PA VanEck Morningstar Develo.. 3.77 % 0.00 %

N/A

USD 1.63B
FLDM:CA 2.00 % 0.44 %

N/A

N/A
DPK 0.00 % 0.96 %

N/A

N/A
EFAV iShares MSCI EAFE Min Vol.. 0.00 % 0.20 %

N/A

USD 7.36B
EFO ProShares Ultra MSCI EAFE 0.00 % 0.95 %

N/A

USD 0.01B
EFU ProShares UltraShort MSCI.. 0.00 % 0.95 %

N/A

N/A
EFZ ProShares Short MSCI EAFE 0.00 % 0.95 %

N/A

N/A
EPV ProShares UltraShort FTSE.. 0.00 % 0.95 %

N/A

USD 0.02B
PDEV 0.00 % 0.00 %

N/A

N/A
UPV ProShares Ultra FTSE Euro.. 0.00 % 0.95 %

N/A

N/A
MVAE:PA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.88% 59% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.88% 59% D- 63% D
Trailing 12 Months  
Capital Gain 15.34% 71% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.34% 68% D+ 65% D
Trailing 5 Years  
Capital Gain 0.29% 72% C 57% F
Dividend Return 11.85% 58% F 30% F
Total Return 12.14% 66% D+ 56% F
Average Annual (5 Year Horizon)  
Capital Gain 0.34% 73% C 45% F
Dividend Return 1.19% 57% F 43% F
Total Return 0.85% 26% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 19.20% 70% C- 86% B+
Risk Adjusted Return 6.21% 53% F 45% F
Market Capitalization 248.88B 100% F 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector